Compare WORX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WORX | PPCB |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | Australia |
| Employees | N/A | 2 |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.9M |
| IPO Year | 2016 | N/A |
| Metric | WORX | PPCB |
|---|---|---|
| Price | $1.07 | $0.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 6.0M |
| Earning Date | 05-14-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,877,629.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.10 |
| 52 Week High | $1.69 | $10.69 |
| Indicator | WORX | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 71.72 | 39.67 |
| Support Level | $0.22 | N/A |
| Resistance Level | N/A | $0.13 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 60.95 | 14.58 |
SCWorx Corp has developed and markets health information technology solutions and associated services that improve healthcare processes and information flow within hospitals. Its software platform enables healthcare providers to simplify, repair, and organize its data, allows the data to be utilized across multiple internal software applications and provides the basis for sophisticated data analytics. The company's solutions are designed to improve the flow of information quickly and accurately between the existing supply chain, electronic medical records, clinical systems, and patient billing functions. It operates in a single segment - health information technology solutions and services, located in a single geographic location - the United States.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.